中国组织工程研究与临床康复
中國組織工程研究與臨床康複
중국조직공정연구여림상강복
JOURNAL OF CLINICAL REHABILITATIVE TISSUE ENGINEERING RESEARCH
2010年
8期
1382-1385
,共4页
杨静%江森明%曹漫明%丁为民%胡喜钢%孟辉%王泽新
楊靜%江森明%曹漫明%丁為民%鬍喜鋼%孟輝%王澤新
양정%강삼명%조만명%정위민%호희강%맹휘%왕택신
表柔比星%壳聚糖%载药缓释微球%微波%小鼠皮下肝癌%控制释放载体材料
錶柔比星%殼聚糖%載藥緩釋微毬%微波%小鼠皮下肝癌%控製釋放載體材料
표유비성%각취당%재약완석미구%미파%소서피하간암%공제석방재체재료
背景:原发性肝癌的手术切除率较低,肝癌的局部治疗成为重要手段.经皮微波消融治疗能达到原位灭活的目的,但不能彻底杀灭瘤细胞.缓释剂型化疗药物可形成局部较高药物浓度及发挥较持久作用,目前已多被应用于原发性肝癌的治疗.目的:观察负载表柔比星的壳聚糖微球联合微波消融局部治疗荷肝癌小鼠皮下移植瘤的效果.方法:采用W/O型乳化-固化法制各表柔比星-壳聚糖微球,扫描电镜观察壳聚糖微球的表面形态,粒径大小.紫外分光光度计分析载药微球的包封率、载药量及药物累积释放率.将24只H22皮下肝癌荷瘤小鼠分成4组,各组皮下肝癌肿瘤分给予以下治疗:单纯微波治疗;微波治疗后第2天给予瘤内注射生理盐水;微波治疗后给予瘤内注射表柔比星;微波治疗后联合瘤内注射载药微球,监测荷瘤小鼠肿瘤体积变化并计算抑瘤率.结果与结论:壳聚糖微球平均粒径约为105 μm,粒径大小较一致,包封率约为80%,载药率约为11%,2周的累积缓释率为84%.微波联合瘤内注射生理盐水、表柔比星、载药微球的抑瘤率分别为8%,20%,47%.表明壳聚糖微球是一种有效的表柔比星局部缓释剂型,联合微波消融治疗有较强的抑瘤作用.
揹景:原髮性肝癌的手術切除率較低,肝癌的跼部治療成為重要手段.經皮微波消融治療能達到原位滅活的目的,但不能徹底殺滅瘤細胞.緩釋劑型化療藥物可形成跼部較高藥物濃度及髮揮較持久作用,目前已多被應用于原髮性肝癌的治療.目的:觀察負載錶柔比星的殼聚糖微毬聯閤微波消融跼部治療荷肝癌小鼠皮下移植瘤的效果.方法:採用W/O型乳化-固化法製各錶柔比星-殼聚糖微毬,掃描電鏡觀察殼聚糖微毬的錶麵形態,粒徑大小.紫外分光光度計分析載藥微毬的包封率、載藥量及藥物纍積釋放率.將24隻H22皮下肝癌荷瘤小鼠分成4組,各組皮下肝癌腫瘤分給予以下治療:單純微波治療;微波治療後第2天給予瘤內註射生理鹽水;微波治療後給予瘤內註射錶柔比星;微波治療後聯閤瘤內註射載藥微毬,鑑測荷瘤小鼠腫瘤體積變化併計算抑瘤率.結果與結論:殼聚糖微毬平均粒徑約為105 μm,粒徑大小較一緻,包封率約為80%,載藥率約為11%,2週的纍積緩釋率為84%.微波聯閤瘤內註射生理鹽水、錶柔比星、載藥微毬的抑瘤率分彆為8%,20%,47%.錶明殼聚糖微毬是一種有效的錶柔比星跼部緩釋劑型,聯閤微波消融治療有較彊的抑瘤作用.
배경:원발성간암적수술절제솔교저,간암적국부치료성위중요수단.경피미파소융치료능체도원위멸활적목적,단불능철저살멸류세포.완석제형화료약물가형성국부교고약물농도급발휘교지구작용,목전이다피응용우원발성간암적치료.목적:관찰부재표유비성적각취당미구연합미파소융국부치료하간암소서피하이식류적효과.방법:채용W/O형유화-고화법제각표유비성-각취당미구,소묘전경관찰각취당미구적표면형태,립경대소.자외분광광도계분석재약미구적포봉솔、재약량급약물루적석방솔.장24지H22피하간암하류소서분성4조,각조피하간암종류분급여이하치료:단순미파치료;미파치료후제2천급여류내주사생리염수;미파치료후급여류내주사표유비성;미파치료후연합류내주사재약미구,감측하류소서종류체적변화병계산억류솔.결과여결론:각취당미구평균립경약위105 μm,립경대소교일치,포봉솔약위80%,재약솔약위11%,2주적루적완석솔위84%.미파연합류내주사생리염수、표유비성、재약미구적억류솔분별위8%,20%,47%.표명각취당미구시일충유효적표유비성국부완석제형,연합미파소융치료유교강적억류작용.
BACKGROUND: The surgical resection rate of pdmary hepatic carcinoma is low, thus, the local treatment arose more attention. Microwave coagulation therapy can inactivate rather than kill the hepatic carcinoma ceils. Slow-release chemotherapy has been used in treating primary hepatic carcinoma because it can form local high concentrations and last for a long time. OBJECTIVE: To observe the therapeutic effect of epirubicin-loaded chitosan microspheres combined with microwave coagulation on treating hepatocellular carcinoma in mica. METHODS: Epirubicin-loaded chitosan microspheres were prepared by using emulsion-chemical cross linking technique. The surface morphology and particles size of chitosan microspheres were observed by scanning electron microscope. Ultraviolet speotrophotometer was used to analyze the entrapment efficiency, entrapment efficiency and cumulative release rates of epirubicin-loaded chitosan microspheres. Totally 24 mice with transplanted subcutaneous H22 HCC were divided into 4 groups, which were respectively treated by microwave coagulation therapy, intratumoral injected with physiological saline after microwave coagulation therapy, intratumoral injected with epirubicin after microwave coagulation therapy, intratumoral injected with epirubicin-ioaded chitosan microspheres after microwave coagulation therapy. The tumor inhibitory rate was calculated. RESULTS AND CONCLUSION: The average diameter of chitosan microsphere was 105 μm, with uniformed particle diameter. The ratio of drug loading was 11% and the entrapment was 80%. The in vitro drug cumulative release rate was 84% after 2 weeks. The tumor inhibitory rates of the microwave coagulation combined with physiological saline, epirubicin, and drug carried microspheres groups were 8%, 20%, and 47%. It suggested that chitosan microsphere is a safe and effective slow-release dosage form, which exhibits strong anti-tumor effect when combined with microwave treatment.